Astrazeneca (AZN) Cash from Restructuring (2009 - 2014)
Astrazeneca (AZN) posted quarterly Cash from Restructuring of $84.3 million for Q2 2014, up 1304.6% year-over-year from $6.0 million in Q2 2013, and up 182.67% quarter-over-quarter from -$102.0 million in Q1 2014.
Astrazeneca (AZN) Cash from Restructuring (2009 - 2014) Analysis & Trends
Astrazeneca's Cash from Restructuring history runs 6 years deep, the most recent figure standing at $84.3 million for Q2 2014.
- In Q2 2014, Cash from Restructuring rose 1304.6% year-over-year to $84.3 million; the TTM figure through Dec 2016 stood at $84.3 million (changed N/A YoY), while the FY2016 annual figure was -$9.7 million, changed N/A from the prior year.
- Cash from Restructuring for Q2 2014 stood at $84.3 million, up from -$102.0 million in the prior quarter.
- The five-year high for Cash from Restructuring was $84.3 million in Q2 2014, with the low at -$102.0 million in Q1 2014.
- The 5-year median for Cash from Restructuring is -$5.0 million (2013), against an average of -$7.4 million.
- Peak annual rise in Cash from Restructuring reached 1304.6% in 2014, while the deepest fall reached 3300.0% in 2014.
- Astrazeneca's Cash from Restructuring stood at -$10.0 million in 2010, then jumped by 90.0% to -$1.0 million in 2011, then surged by 200.0% to $1.0 million in 2012, then sank by 800.0% to -$7.0 million in 2013, then surged by 1304.6% to $84.3 million in 2014.
- Business Quant data shows AZN's Cash from Restructuring at $84.3 million in Q2 2014, -$102.0 million in Q1 2014, and -$7.0 million in Q2 2013.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Johnson & Johnson | 651.30 Bn | 630.54 Bn | 17.26 Bn |
| 2 | AbbVie | 468.64 Bn | 462.07 Bn | 12.70 Bn |
| 3 | Merck | 378.89 Bn | 371.74 Bn | 12.21 Bn |
| 4 | Novartis Ag | 300.89 Bn | 293.20 Bn | 11.24 Bn |
| 5 | Astrazeneca | 257.36 Bn | 252.46 Bn | 12.86 Bn |
| 6 | Amgen | 236.69 Bn | 222.70 Bn | 7.24 Bn |
| 7 | Gilead Sciences | 182.15 Bn | 178.97 Bn | 6.22 Bn |
| 8 | Pfizer | 161.31 Bn | 149.61 Bn | 10.94 Bn |
| 9 | Gsk | 105.67 Bn | 101.50 Bn | 8.24 Bn |
| 10 | Sanofi | 54.97 Bn | 47.59 Bn | 10.79 Bn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2014 | 84.32 Mn |
| Mar 31, 2014 | -102.00 Mn |
| Jun 30, 2013 | -7.00 Mn |
| Mar 31, 2013 | -3.00 Mn |
| Sep 30, 2012 | 1.00 Mn |
| Jun 30, 2012 | -1.00 Mn |
| Mar 31, 2012 | -20.00 Mn |
| Jun 30, 2011 | -1.00 Mn |
| Mar 31, 2011 | -15.00 Mn |
| Mar 31, 2010 | -10.00 Mn |
| Dec 31, 2009 | 21.00 Mn |
| Sep 30, 2009 | -20.00 Mn |
| Jun 30, 2009 | 1.00 Mn |
| Mar 31, 2009 | 9.00 Mn |